Source comparison
How Long TB-500 Takes to Work: Dosing Protocol Comparison
The table below compares three common TB-500 dosing protocols and their typical timelines for observable tissue repair across different injury types. Timelines represent average ranges from published research models and investigational protocols. Standard Load
This comparison does not assign a generated winner or score.
- The table below compares three common TB-500 dosing protocols and their typical timelines for observable tissue repair across different injury types. Timelines represent average ranges from published research models and investigational protocols.
- Standard Loading
- 2.5mg twice weekly for 4–6 weeks, then 2.5mg once weekly
- 10–14 days for initial improvement; 3–4 weeks for functional recovery
- 4–6 weeks for initial improvement; 8–12 weeks for structural repair
- 5–10 days for inflammatory marker reduction
- Most evidence-backed protocol for acute injuries; balances efficacy with cost and injection frequency
- High-Dose Accelerated
- 5mg twice weekly for 4 weeks, then 2.5mg twice weekly for 4 weeks
- 7–10 days for initial improvement; 2–3 weeks for functional recovery
- 3–5 weeks for initial improvement; 6–10 weeks for structural repair
- 3–7 days for inflammatory marker reduction
- Faster subjective timelines but minimal objective advantage over standard dosing; higher cost without proportional benefit for most applications
- Maintenance Only
- 2mg once weekly continuously
- 14–21 days for initial improvement; 4–6 weeks for functional recovery
- 6–8 weeks for initial improvement; 12–16 weeks for structural repair
- 7–14 days for inflammatory marker reduction
- Slower timelines but sustainable for chronic conditions; appropriate for long-term systemic applications rather than acute injury
- The standard loading protocol represents the most commonly cited approach in published literature and balances timeline efficiency with practical considerations like injection burden and peptide cost. High-dose accelerated protocols shorten timelines by 20–30% for acute injuries but offer diminishing returns for chronic conditions. Maintenance-only dosing is appropriate for long-term systemic use (chronic inflammation, cardiovascular applications, neurological recovery) where timeline urgency is secondary to sustained benefit.